Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献

{"title":"Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis.","authors":"Daniele Caliendo,&nbsp;Anna Puca,&nbsp;Luigi Lavorgna,&nbsp;Antonio Carotenuto,&nbsp;Maria Petracca,&nbsp;Roberta Lanzillo,&nbsp;Vincenzo Brescia Morra,&nbsp;Marcello Moccia","doi":"10.1177/20552173231202123","DOIUrl":"10.1177/20552173231202123","url":null,"abstract":"<p><strong>Introduction: </strong>Gait impairment is common in multiple sclerosis (MS), but difficult to evaluate in clinical practice. In this proof-of-concept observational study, we compared walking ability recorded by Google Maps Timeline to conventional clinical measures in people with MS.</p><p><strong>Methods: </strong>We used open-access Google Maps Timeline to record the total number of days with walking activity, walking distance, walking time, and walking speed. Each Google Maps Timeline variable was included in a different stepwise linear regression model including all conventional clinical variables.</p><p><strong>Results: </strong>We included nine people with MS (age 43.1 ± 6.6 years; females 55.6%; disease duration 12.7 ± 3.1 years; median Expanded Disability Status Scale 3.0 (range 1.0-5.5)). Higher percentage of days with recorded walking was associated with lower Fatigue Severity Scale (<i>p</i> = 0.01), and higher MS Walking Scale (<i>p</i> = 0.04). Longer average daily walking distance was associated with shorter Timed-25 Foot Walking Test (<i>p</i> = 0.02), lower Expanded Disability Status Scale (<i>p</i> = 0.01), and higher Euro-Quality of Life (<i>p</i> = 0.04). Longer average daily walking time was associated with shorter Timed-25 Foot Walking Test (<i>p</i> = 0.03). Higher walking speed was associated with lower Fatigue Severity Scale (<i>p</i> = 0.04).</p><p><strong>Conclusion: </strong>Google Maps Timeline parameters provide actual estimates of daily walking activities in MS.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231202123"},"PeriodicalIF":2.8,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/29/10.1177_20552173231202123.PMC10505345.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry.","authors":"Xiaotong Jiang, Gabrielle Simoneau, Mel Zuercher, Yanic Heer, Philip van Hoevell, Adrian Harrington, Wanda Castro-Borrero, Carl de Moor, Fabio Pellegrini, Lu Tian, Arnfin Bergmann, Stefan Braune","doi":"10.1177/20552173231194353","DOIUrl":"10.1177/20552173231194353","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) comparative effectiveness research needs to go beyond average treatment effects (ATEs) and post-host subgroup analyses.</p><p><strong>Objective: </strong>This retrospective study assessed overall and patient-specific effects of dimethyl fumarate (DMF) versus teriflunomide (TERI) in patients with relapsing-remitting MS.</p><p><strong>Methods: </strong>A novel precision medicine (PM) scoring approach leverages advanced machine learning methods and adjusts for imbalances in baseline characteristics between patients receiving different treatments. Using the German NeuroTransData registry, we implemented and internally validated different scoring systems to distinguish patient-specific effects of DMF relative to TERI based on annualized relapse rates, time to first relapse, and time to confirmed disease progression.</p><p><strong>Results: </strong>Among 2791 patients, there was superior ATE of DMF versus TERI for the two relapse-related endpoints (<i>p</i> = 0.037 and 0.018). Low to moderate signals of treatment effect heterogeneity were detected according to individualized scores. A MS patient subgroup was identified for whom DMF was more effective than TERI (<i>p</i> = 0.013): older (45 versus 38 years), longer MS duration (110 versus 50 months), not newly diagnosed (74% versus 40%), and no prior glatiramer acetate usage (35% versus 5%).</p><p><strong>Conclusion: </strong>The implemented approach can disentangle prognostic differences from treatment effect heterogeneity and provide unbiased patient-specific profiling of comparative effectiveness based on real-world data.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231194353"},"PeriodicalIF":2.8,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/96/10.1177_20552173231194353.PMC10460475.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.","authors":"Ide Smets, Matthijs Versteegh, Simone Huygens, Cato Corsten, Beatrijs Wokke, Joost Smolders","doi":"10.1177/20552173231189398","DOIUrl":"10.1177/20552173231189398","url":null,"abstract":"<p><strong>Background: </strong>In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label drugs.</p><p><strong>Objective: </strong>Comparing differences in benefits between anti-CD20 mAbs from a health-economic and societal perspective.</p><p><strong>Methods: </strong>To reflect lifetime use of DMTs, we used a treatment-sequence model to compare ocrelizumab/ofatumumab and eight other drug classes in terms of health (lifetime relapses, time to Expanded Disability Status Scale [EDSS] 6, lifetime quality-adjusted life years) and cost-effectiveness (net health benefit). To become cost-effective compared to ocrelizumab, we modelled the list price of ublituximab and desired effect on EDSS progression of rituximab.</p><p><strong>Results: </strong>Although drug sequences with ocrelizumab in first- and second-line were more cost-effective than ofatumumab, our probabilistic analysis suggests this outcome was very uncertain. To be more cost-effective than ocrelizumab, ublituximab needs to be about 25% cheaper whilst rituximab needs to equal the effect on disability progression seen with first-line treatments.</p><p><strong>Conclusions: </strong>Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231189398"},"PeriodicalIF":2.5,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-training working memory/information processing capabilities and brain atrophy limit the improving effects of cognitive training.","authors":"Sónia Félix Esbrí,&nbsp;Alba Sebastián Tirado,&nbsp;Maria Zaragoza Mezquita,&nbsp;Carla Sanchis Segura,&nbsp;Cristina Forn","doi":"10.1177/20552173231196990","DOIUrl":"https://doi.org/10.1177/20552173231196990","url":null,"abstract":"<p><strong>Background: </strong>Computerized training in persons with multiple sclerosis (PwMS) seems to enhance working memory (WM)/information processing (IP), but factors associated with the efficacy of the treatment have not been sufficiently explored. Objective: To identify clinical and radiological characteristics associated with positive WM/IP training responses.</p><p><strong>Methods: </strong>Radiological and neuropsychological assessments were carried out on a sample of 35 PwMs who were divided into \"WM/IP-impaired\" and \"WM/IP-preserved.\" All participants underwent adaptive n-back training for 10 days and were assessed post-training. Between-group differences (\"WM/IP-impaired\" vs. \"WM/IP-preserved\") in training-induced cognitive improvement were assessed and exploratory correlational/ regression-based methods were employed to assess the relationship between cognitive improvement and clinical and radiological variables.</p><p><strong>Results: </strong>All PwMS exhibited WM/IP benefits after training, but those with preserved WM/IP functions showed greater positive effects as well as transfer effects to other WM/IP tests when compared to the impaired group. Additional analyses revealed that positive response to treatment was associated with WM/IP baseline capabilities and greater gray matter volume (GMVOL) in relevant areas such as the thalamus.</p><p><strong>Conclusions: </strong>Restorative cognitive training is suitable to improve cognition in PwMS but its effective outcome differs depending on the baseline WM/IP capabilities and GMVOL.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231196990"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/66/10.1177_20552173231196990.PMC10483983.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10275569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis.","authors":"Jagriti Jackie Bhattarai,&nbsp;Krina S Patel,&nbsp;Katherine M Dunn,&nbsp;Aeysha Brown,&nbsp;Brett Opelt,&nbsp;Abbey J Hughes","doi":"10.1177/20552173231194352","DOIUrl":"https://doi.org/10.1177/20552173231194352","url":null,"abstract":"<p><p>Sleep disturbance is common in people with multiple sclerosis and may worsen fatigue; however, the assessment of sleep-fatigue relationships varies across studies. To better understand sleep-fatigue relationships in this population, we conducted a systematic review and random effects meta-analyses for the associations between fatigue and 10 sleep variables: Sleep-disordered breathing, daytime sleepiness, sleep quality, insomnia, restless legs, number of awakenings, sleep efficiency, sleep latency, sleep duration, and wake after sleep onset. Of the 1062 studies screened, 46 met inclusion criteria and provided sufficient data for calculating Hedges' g. Study quality was assessed using the Newcastle-Ottawa Scale. Sample characteristics did not differ between the 10 analyses. Results indicated that sleep quality and insomnia (assessed via self-report or diagnostic criteria) were strongly associated with fatigue (all <i>g</i>s ≥ 0.80 and all <i>ps</i> < .001). In contrast, the number of awakenings and sleep duration (assessed objectively) were not significantly associated with fatigue. Remaining sleep variables yielded moderate, significant effects. Most effects did not vary based on study quality or sample demographics. Results highlight that insomnia and perceptions of poor sleep have a stronger link than objective sleep duration to fatigue in multiple sclerosis and may represent a more effective target for intervention.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231194352"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/bd/10.1177_20552173231194352.PMC10460472.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor on \"new algorithmic approach for easier and faster extended disability status scale calculation\".","authors":"Amr M Fouad","doi":"10.1177/20552173231198378","DOIUrl":"https://doi.org/10.1177/20552173231198378","url":null,"abstract":"We stated that “Most of them provide little information about the specific rules used to estimate the FS scores and EDSS steps” and “None of these tools give a clear way to calculate the FS based on a complete neurological assessment.” In fact, we were not the first to make such observations, D’Souza and colleagues made the same observations regarding these electronic applications in a study they published in 2017.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231198378"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/00/10.1177_20552173231198378.PMC10467176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10138086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The socioeconomic impact of disability progression in multiple sclerosis: A retrospective cohort study of the German NeuroTransData (NTD) registry.","authors":"Paul Dillon,&nbsp;Yanic Heer,&nbsp;Eleni Karamasioti,&nbsp;Erwan Muros-Le Rouzic,&nbsp;Guiseppe Marcelli,&nbsp;Danilo Di Maio,&nbsp;Stefan Braune,&nbsp;Gisela Kobelt,&nbsp;Jürgen Wasem","doi":"10.1177/20552173231187810","DOIUrl":"https://doi.org/10.1177/20552173231187810","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is a progressively debilitating neurologic disease that poses significant costs to the healthcare system and workforce.</p><p><strong>Objective: </strong>To evaluate the impact of MS disease progression on societal costs and quality of life (QoL) using data from the German NeuroTransData (NTD) MS registry.</p><p><strong>Methods: </strong>Cross-sectional cohort study. The cost cohort included patients with MS disability assessed using Expanded Disability Status Scale (EDSS) in 2019 while the QoL cohort included patients assessed using EDSS and EuroQol-5 Dimension 5-Levels between 2009 and 2019. Direct and indirect medical, and non-medical resource use was quantified and costs derived from public sources.</p><p><strong>Results: </strong>Within the QoL cohort (<i>n</i> = 9821), QoL worsened with increasing EDSS. Within the cost cohort (<i>n</i> = 7286), increasing resource use with increasing EDSS was observed. Societal costs per patient, excluding or including disease-modifying therapies, increased from €5694 or €19,315 at EDSS 0 to 3.5 to €25,419 or €36,499 at EDSS 4 to 6.5, and €52,883 or €58,576 at EDSS 7 to 9.5. In multivariate modeling, each 0.5-step increase in EDSS was significantly associated with increasing costs, and worsening QoL.</p><p><strong>Conclusion: </strong>This study confirms the major socioeconomic burden associated with MS disability progression. From a socioeconomic perspective, delaying disability progression may benefit patients and society.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231187810"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/35/10.1177_20552173231187810.PMC10387702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10304671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey.","authors":"Hayrettin Tumani,&nbsp;Patricia K Coyle,&nbsp;Claudia Cárcamo,&nbsp;Cinzia Cordioli,&nbsp;Pablo A López,&nbsp;Marek Peterka,&nbsp;Cristina Ramo-Tello,&nbsp;María I Zuluaga,&nbsp;Thijs Koster,&nbsp;Megan Vignos","doi":"10.1177/20552173231198588","DOIUrl":"https://doi.org/10.1177/20552173231198588","url":null,"abstract":"<p><strong>Background: </strong>People over age 50-55 have historically been excluded from randomized clinical trials for multiple sclerosis (MS). However, more than half of those living with an MS diagnosis are over 55.</p><p><strong>Objective: </strong>Explore the unique considerations of treating older people with MS (PwMS) using an iterative and structured Delphi-based assessment to gather expert opinions.</p><p><strong>Methods: </strong>Eight MS neurologists with an interest in older PwMS developed a 2-round survey. Survey respondents were qualified neurologists with ≥3 years' experience, personally responsible for treatment decisions, and treating ≥20 patients per month, of whom ≥10% were ≥50 years old. Consensus was defined as ≥75% agreement on questions with categorical responses or as a mean score ≥4 on questions with numerical responses.</p><p><strong>Results: </strong>In Survey 1, 224 neurologists responded; 180 of these completed Survey 2. Limited consensus was reached with varying levels of agreement on several topics including identification and assessment of older patients; factors relating to treatment decisions including immunosenescence and comorbidities; considerations for high-efficacy treatments; de-escalation or discontinuation of treatment; effects of COVID-19; and unmet needs for treating this population.</p><p><strong>Conclusion: </strong>The results of this Delphi process highlight the need for targeted studies to create guidance for the care of older PwMS.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231198588"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/a3/10.1177_20552173231198588.PMC10501080.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case series in individuals with multiple sclerosis using direct current electrical stimulation to inhibit spasticity and improve functional outcomes.","authors":"Courtney L Ellerbusch,&nbsp;Kristina M Chapple,&nbsp;Julie B Seibert","doi":"10.1177/20552173231186512","DOIUrl":"https://doi.org/10.1177/20552173231186512","url":null,"abstract":"<p><strong>Background and purpose: </strong>Multiple sclerosis (MS) has a high incidence of debilitating spasticity. Central Nervous System (CNS) intrafusal settings have an impact on spasticity level. Mechanoreceptors of the Peripheral Nervous System (PNS) communicate monosynaptically with the central nervous system (CNS). This case series assesses feasibility of multimodal treatment of individuals with MS using a direct current electrical stimulation (DC) to influence mechanoreceptors.</p><p><strong>Case description and intervention: </strong>Seven MS diagnosed participants with Expanded Disability Status Scale (EDSS) = 6.0-8.0 completed 18 visits over 6 weeks of using DC combined with neuromuscular reeducation. Design included pre-, post- outcome measures of EDSS, 12-item MS Walking Scale (MSWS-12), Range of Motion (ROM), Manual Muscle Testing (MMT), Modified Ashworth Test (MAT), Timed 25-Foot walk (T25WT), Timed Up and Go (TUG) and the Multiple Sclerosis Impact Scale-29 (MSIS-29).</p><p><strong>Outcome: </strong>125 out of a possible 126 visits were completed, demonstrating a high level of tolerance. Individual results included trends towards improvement in spasticity and agonists.</p><p><strong>Discussion: </strong>This case series design of seven heterogenous subjects with MS is a low sample size for statistical analysis and should be considered a pilot. The study demonstrates a high level of feasibility and possible correlations to consider. Further research is warranted.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231186512"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/87/10.1177_20552173231186512.PMC10350763.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10353113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional connectome fingerprinting and stability in multiple sclerosis.","authors":"Maron Mantwill,&nbsp;Susanna Asseyer,&nbsp;Claudia Chien,&nbsp;Joseph Kuchling,&nbsp;Tanja Schmitz-Hübsch,&nbsp;Alexander U Brandt,&nbsp;John-Dylan Haynes,&nbsp;Friedemann Paul,&nbsp;Carsten Finke","doi":"10.1177/20552173231195879","DOIUrl":"https://doi.org/10.1177/20552173231195879","url":null,"abstract":"<p><strong>Background: </strong>Functional connectome fingerprinting can identify individuals based on their functional connectome. Previous studies relied mostly on short intervals between fMRI acquisitions.</p><p><strong>Objective: </strong>This cohort study aimed to determine the stability of connectome-based identification and their underlying signatures in patients with multiple sclerosis and healthy individuals with long follow-up intervals.</p><p><strong>Methods: </strong>We acquired resting-state fMRI in 70 patients with multiple sclerosis and 273 healthy individuals with long follow-up times (up to 4 and 9 years, respectively). Using functional connectome fingerprinting, we examined the stability of the connectome and additionally investigated which regions, connections and networks supported individual identification. Finally, we predicted cognitive and behavioural outcome based on functional connectivity.</p><p><strong>Results: </strong>Multiple sclerosis patients showed connectome stability and identification accuracies similar to healthy individuals, with longer time delays between imaging sessions being associated with accuracies dropping from 89% to 76%. Lesion load, brain atrophy or cognitive impairment did not affect identification accuracies within the range of disease severity studied. Connections from the fronto-parietal and default mode network were consistently most distinctive, i.e., informative of identity. The functional connectivity also allowed the prediction of individual cognitive performances.</p><p><strong>Conclusion: </strong>Our results demonstrate that discriminatory signatures in the functional connectome are stable over extended periods of time in multiple sclerosis, resulting in similar identification accuracies and distinctive long-lasting functional connectome fingerprinting signatures in patients and healthy individuals.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 3","pages":"20552173231195879"},"PeriodicalIF":2.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/a1/10.1177_20552173231195879.PMC10460476.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}